Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.” ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector ...

In Q4, Dupixent grew by 16% from strong prescription ... you have the full data a few weeks after injection, and we know very well that RSV -- are going to go still in January, February and ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

A doctor may prescribe injectable treatments, such as methotrexate, TNF-alpha inhibitors, or interleukin inhibitors, for moderate to severe psoriasis when other treatments don’t work.

“For most patients who experienced anaphylaxis with glatiramer acetate use, the symptoms appeared within one hour of injection. In some cases, anaphylaxis resulted in hospitalization and death ...

The company’s lead products include Eylea injection for treating wet age-related ... The company’s other growth driver, Dupixent, is also doing well, helping shrug off sales slowdown in ...

Glenmark Pharmaceuticals on Tuesday said its US arm has launched anticoagulant Phytonadione injectable emulsion. Glenmark Pharmaceuticals Inc., USA has launched Phytonadione injectable emulsion of ...